Clinical Report: The Most Sensitive Cancer Blood Test Yet

Overview

Researchers have developed an ultra-sensitive blood test capable of detecting cancer-related microRNAs at unprecedented low levels. This test shows promise for early cancer diagnosis and monitoring treatment efficacy.

Background

The early detection of cancer significantly improves treatment outcomes, yet current screening methods often fail to identify tumors at their nascent stages. Liquid biopsy technologies, particularly those targeting microRNAs, offer a non-invasive approach to detect cancer biomarkers in the blood. This advancement could revolutionize cancer screening and monitoring, making it crucial for healthcare professionals to stay informed about emerging technologies.

Data Highlights

The new optical sensing system can detect microRNAs at sub-attomolar levels, with a detection limit of 168 zeptomolar, outperforming standard laboratory methods.

Key Findings

• The test detects cancer-related microRNAs, such as miRNA-21, miRNA-155, and miRNA-10b, linked to early tumor development.
• It utilizes second-harmonic generation (SHG) light signals to measure microRNA concentrations with high sensitivity.
• The system demonstrated stronger signal differences between lung cancer patients and healthy individuals compared to standard RT-qPCR testing.
• It allows for potential daily or weekly monitoring of biomarker levels to assess treatment efficacy.
• Lead researcher Han Zhang emphasized its promise for enabling simple blood screenings for lung cancer before tumors are visible on imaging.

Clinical Implications

This ultra-sensitive blood test could facilitate earlier cancer detection and improve personalized treatment strategies. Clinicians may consider integrating such tests into routine practice for monitoring patients at high risk for lung cancer.

Conclusion

The development of this highly sensitive blood test represents a significant advancement in cancer diagnostics, with the potential to enhance early detection and treatment monitoring.

References

1. The ASCO Post, 2025 -- Novel Strategy May Enhance Sensitivity, Accuracy of Monitoring Cancer in Blood Samples
2. The New Gastroenterologist, 2025 -- Innovative Blood Test Shows Potential for Colorectal Cancer Screening in Average-Risk Adults
3. The ASCO Post, 2024 -- Common Blood Tests May Improve Early Cancer Diagnosis
4. The ASCO Post, 2025 -- Cancer May Be Detectable in Bloodstream 3 Years Prior to Diagnosis
5. Cancer Screening Tests | Cancer | CDC -- Cancer Screening Tests
6. npj Precision Oncology -- A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening
7. Cancer Screening Tests | Cancer | CDC
8. A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening | npj Precision Oncology
9. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Testicular-Cancer-2025.pdf